Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Int J Cancer. 2012 Apr 24;131(11):2562–2572. doi: 10.1002/ijc.27534

Figure 1.

Figure 1

Induction of targeted antibodies by phDR5 DNA electrovaccination. A. BALB/c mice were electrovaccinated four times at two week intervals with an admix of plasmid DNA encoding mouse GM-CSF and human DR5 (50 μg each). Control groups received pGM-CSF and blank vector pVax1. B. Mouse immune sera were tested at 1:20 dilution for specific binding to NIH3T3 cells stably transfected with human DR5 (3T3/hDR5). Flow cytometric histograms showed the binding of hDR5 immune serum (upper panels, shaded histogram) and hDR5 mAb HS201 (lower panels, shaded histogram) to 3T3/hDR5 and SUM159 cells. NIH 3T3 cells (left panels) and non-immune control serum (open histogram) were the negative controls. C. The levels of anti-hDR5 specific IgG in immune sera were quantified by ELISA using recombinant hDR5 (aa 1-182) fused to human IgG Fc (hDR5-Fc). Control wells contained recombinant hHer2 fused to human IgG Fc (hHer2-Fc). (n=10 per group).